z-logo
Premium
Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All‐Cause Mortality in Kidney Transplant Recipients
Author(s) -
Dahle D. O.,
Åsberg A.,
Hartmann A.,
Holdaas H.,
Bachtler M.,
Jenssen T. G.,
Dionisi M.,
Pasch A.
Publication year - 2016
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.13443
Subject(s) - medicine , hazard ratio , cardiology , calcification , kidney disease , proportional hazards model , kidney transplantation , transplantation , confidence interval
Calcification of the vasculature is associated with cardiovascular disease and death in kidney transplant recipients. A novel functional blood test measures calcification propensity by quantifying the transformation time (T 50 ) from primary to secondary calciprotein particles. Accelerated T 50 indicates a diminished ability of serum to resist calcification. We measured T 50 in 1435 patients 10 weeks after kidney transplantation during 2000–2003 (first era) and 2009–2012 (second era). Aortic pulse wave velocity (APWV) was measured at week 10 and after 1 year in 589 patients from the second era. Accelerated T 50 was associated with diabetes, deceased donor, first transplant, rejection, stronger immunosuppression, first era, higher serum phosphate and lower albumin. T 50 was not associated with progression of APWV. During a median follow‐up of 5.1 years, 283 patients died, 70 from myocardial infarction, cardiac failure or sudden death. In Cox regression models, accelerated T 50 was strongly and independently associated with both all‐cause and cardiac mortality, low versus high T 50 quartile: hazard ratio 1.60 (95% confidence interval [CI] 1.00–2.57), p trend   = 0.03, and 3.60 (95% CI 1.10–11.83), p trend   = 0.02, respectively. In conclusion, calcification propensity (T 50 ) was strongly associated with all‐cause and cardiac mortality of kidney transplant recipients, potentially via a cardiac nonAPWV‐related pathway. Whether therapeutic improvement of T 50 improves outcome awaits clarification in a randomized trial.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom